Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.112.300346PMID 23175674PMCID PMC3908828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antidiabetic actions of a non–agonist PPARγ ligand blocking Cdk5–mediated phosphorylation

  2012cited by this paper
• Pioglitazone for diabetes prevention in impaired glucose tolerance.

  2011cited by this paper
• Endothelial Surface N-Glycans Mediate Monocyte Adhesion and Are Targets for Anti-inflammatory Effects of Peroxisome Proliferator-activated Receptor γ Ligands*

  2011cited by this paper
• Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation

  2011cited by this paper
• Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes

  2011cited by this paper
• Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruct

  2011cited by this paper
• Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

  2010cited by this paper
• Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study

  2010cited by this paper
• Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

  2009cited by this paper
• BMC Endocrine Disorders BioMed Central Study protocol Actos Now for the prevention of diabetes (ACT NOW) study

  2009cited by this paper
• Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.

  2008cited by this paper
• The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

  2008cited by this paper
• Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus

  2008cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.

  2005cited by this paper
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Increased CD36 protein as a response to defective insulin signaling in macrophages.

  2004cited by this paper
• Rosiglitazone (PPARγ‐agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes–atherosclerosis mouse model

  2003cited by this paper
• Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Estrogen in the Prevention of Atherosclerosis

  2001cited by this paper
• PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.

  2001cited by this paper
• Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice

  2001cited by this paper
• Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL

  2001cited by this paper
• Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

  2001cited by this paper
• Diabetes and cardiovascular disease

  2000cited by this paper
• Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

  2000cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

  2000cited by this paper
• Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

  1999cited by this paper
• Insulin signaling in the arterial wall.

  1999cited by this paper
• Diabetes and cardiovascular disease.

  1999cited by this paper
• PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

  1998cited by this paper
• PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

  1998cited by this paper
• PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis

  1995cited by this paper
• Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

  1981cited by this paper

• Systematic pharmacology and experimental validation to elucidate the inflammation-associated mechanism of Huanglian Wendan (HLWD) decoction in the treatment of MAFLD associated with atherosclerosis.

  2024cites this paper
• Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis

  2024cites this paper
• 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024.

  2023cites this paper
• Decaffeinated coffee and green tea extract inhibit foam cell atherosclerosis by lowering inflammation and improving cholesterol influx/efflux balance through upregulation of PPARγ and miR-155 [version 2; peer review: awaiting peer review

  2023cites this paper
• Encapsulation of Pioglitazone into Polymer-Nanoparticles for Potential Treatment of Atherosclerotic Diseases.

  2023cites this paper
• Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer’s Disease via Neuroinflammation and Ferroptosis

  2023cites this paper
• Pioglitazone, Bladder Cancer and the Presumption of Innocence.

  2022cites this paper
• Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method

  2022cites this paper
• The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress

  2022cites this paper
• Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes

  2022cites this paper
• PPAR‐γ agonist pioglitazone alleviates inflammatory response induced by lipopolysaccharides in osteoblast cells

  2022cites this paper
• Inflammatory Mechanisms of Diabetes and Its Vascular Complications

  2022cites this paper
• Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance

  2022cites this paper
• Decaffeinated coffee and green tea extract inhibit foam cell atherosclerosis by lowering inflammation and improving cholesterol influx/efflux balance through upregulation of PPARγ and miR-155 [version 1; peer review: awaiting peer review]

  2021cites this paper
• Decaffeinated coffee and green tea extract inhibit foam cell atherosclerosis by lowering inflammation and improving cholesterol influx/efflux balance through upregulation of PPARγ and miR-155

  2021cites this paper
• Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology - A new chance for causative therapy?

  2021cites this paper
• Hypertension in diabetes care: emerging roles of recent hypoglycemic agents

  2021cites this paper
• Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

  2021cites this paper
• Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model

  2021cites this paper
• Mechanistic Insight into PPARγ and Tregs in Atherosclerotic Immune Inflammation

  2021cites this paper
• Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition

  2021cites this paper
• Anti-inflammatory mechanisms of the vascular smooth muscle PPARγ

  2021cites this paper
• Pharmacological interventions for asymptomatic carotid stenosis.

  2020cites this paper
• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.

  2020cites this paper
• Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk

  2020cites this paper
• Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis

  2020cites this paper
• Polymer-based nanoparticles for biomedical applications

  2020cites this paper
• Pioglitazone

  2020cites this paper
• Are Persistent Organic Pollutants Linked to Lipid Abnormalities, Atherosclerosis and Cardiovascular Disease? A Review

  2020cites this paper
• Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis.

  2020cites this paper
• Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.

  2019cites this paper
• Title: Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials. Running title: Vascular risk factors and C-IMT progression 2 Traditional Risk Factors are Causally Related to Carotid Intima-Med

  2019cites this paper
• Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications.

  2019cites this paper
• Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes

  2019cites this paper
• The Drug Candidate BGP-15 Delays the Onset of Diastolic Dysfunction in the Goto-Kakizaki Rat Model of Diabetic Cardiomyopathy

  2019cites this paper
• Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

  2019cites this paper
• Pioglitazone ameliorates hepatic damage in irradiated rats via regulating anti-inflammatory and antifibrogenic signalling pathways

  2019cites this paper
• Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study

  2019cites this paper
• Does diabetes prevention translate into reduced long-term vascular complications of diabetes?

  2019cites this paper
• Diabetes and Cardiovascular Disease

  2019cites this paper
• Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness

  2019cites this paper
• Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials.

  2019cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Recent Advances in Managing Atherosclerosis via Nanomedicine.

  2018cites this paper
• The Vasculature in Prediabetes.

  2018cites this paper
• Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)

  2018influential citation
• Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial

  2018cites this paper
• Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis

  2018cites this paper
• Changes in plasma levels of perfluoroalkyl substances (PFASs) are related to increase in carotid intima-media thickness over 10 years – a longitudinal study

  2018cites this paper
• Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies

  2018cites this paper
• Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT

  2018cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Roles and Clinical Applications of Biomarkers in Cardiovascular Disease 2017

  2017influential citation
• X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs.

  2017cites this paper
• Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea.

  2017cites this paper
• I4, a synthetic anti-diabetes agent, attenuates atherosclerosis through its lipid-lowering, anti-inflammatory and anti-apoptosis properties.

  2017cites this paper
• Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease

  2017cites this paper
• Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial.

  2017cites this paper
• Diabetes mellitus and stroke: Diagnosis, nursing interdisciplinary management, and medical secretary documentation practices

  2017cites this paper
• The current role of glucose control medications in primary and secondary prevention for cardiovascular disease

  2017cites this paper
• Diabetes mellitus and stroke: A clinical update

  2017cites this paper
• Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms

  2017cites this paper
• Pioglitazone and cardiovascular risk reduction: time for a second look?

  2017cites this paper
• Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis

  2017cites this paper
• Pioglitazone Prevents Stroke in Patients with a Recent TIA or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial

  2017cites this paper
• Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

  2017cites this paper
• Effect of Pioglitazone on Cardio-Metabolic Risk in Patients with Obstructive Sleep Apnea

  2017cites this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cites this paper
• SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

  2016cites this paper
• Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance

  2016cites this paper
• Cardiovascular safety of anti-diabetic drugs.

  2016cites this paper
• Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease

  2016cites this paper
• Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance

  2016cites this paper
• Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis

  2016cites this paper
• Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review

  2016cites this paper
• The current role of thiazolidinediones in diabetes management

  2016cites this paper
• Pioglitazone alleviates inflammation in diabetic mice fed a high‐fat diet via inhibiting advanced glycation end‐product‐induced classical macrophage activation

  2016cites this paper
• Reconfiguration of NKT Cell Subset Compartment Is Associated with Plaque Development in Patients with Carotid Artery Stenosis

  2016cites this paper
• Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis.

  2015cites this paper
• Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

  2015cites this paper
• Associations of glycated haemoglobin A1c and glycated albumin with subclinical atherosclerosis in middle‐aged and elderly Chinese population with impaired glucose regulation

  2015cites this paper
• Treating Atherosclerotic Disease: A Still-Unsolved Challenge

  2015cites this paper
• Cthrc1 controls adipose tissue formation, body composition, and physical activity

  2015cites this paper
• Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.

  2015cites this paper
• Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

  2014cites this paper
• Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus

  2014cites this paper
• Reversing Vascular Dysfunction in Rheumatoid Arthritis: Improved Augmentation Index but Not Endothelial Function With Peroxisome Proliferator–Activated Receptor γ Agonist Therapy

  2014cites this paper
• Pioglitazone Increases Serum DPP-4 Level in Type 2 Diabetes Mellitus

  2014cites this paper
• Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases

  2014cites this paper
• The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.

  2014cites this paper
• Phloretin promotes adipocyte differentiation in vitro and improves glucose homeostasis in vivo.

  2014cites this paper
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

  2014cites this paper
• Ectopic visceral fat: A clinical and molecular perspective on the cardiometabolic risk

  2014cites this paper
• Recent highlights of ATVB: diabetes mellitus.

  2014cites this paper
• Concept of Atherosclerosis Velocity: Is It a Better Measure of Cardiovascular Risk?

  2013cites this paper
• MICE WITH GROWTH HORMONE OVER-EXPRESSION

  2013cites this paper
• Pioglitazone does not improve insulin signaling in mice with GH over-expression.

  2013cites this paper
• The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

  2013cites this paper
• More than a simple storage organ: Adipose tissue as a source of adipokines involved in cardiovascular disease

  2013cites this paper